With the development of personalized medicine and precision medicine, therapeutic strategies based on the lncRNA RP11-197K6.1/miR-135a-5p/DLX5 axis are expected to provide more precise and effective treatment options for CRC and other cancers. The gene discussed is DLX5; the disease is cancer.